IDEXX Laboratories, Inc. (IDXX) Gross Margin: 62.05%
Is IDEXX Laboratories, Inc.’s gross margin high or low?
IDEXX Laboratories, Inc.'s gross margin of 62.05% is in line with its 5-year average of 59.83%, near the high end of its 5-year range (58.04%–62.05%).
As of Thursday, June 11, 2026. 1.03% above its 12-month average of 61.42%.
IDXX Gross Margin Chart
IDXX Average Gross Margin Chart
IDXX Current vs Average Gross Margin Chart
IDXX Gross Margin Metrics
GROSS MARGIN
62.05%
GROSS MARGIN AVG TTM
61.42%
GROSS MARGIN AVG 3Y
60.55%
GROSS MARGIN AVG 5Y
59.83%
GROSS MARGIN AVG 10Y
58.01%
GROSS MARGIN AVG 15Y
56.72%
GROSS MARGIN AVG 20Y
55.35%
CURRENT VS TTM AVG
+1.03%
CURRENT VS 3Y AVG
+2.49%
CURRENT VS 5Y AVG
+3.71%
CURRENT VS 10Y AVG
+6.97%
CURRENT VS 15Y AVG
+9.41%
CURRENT VS 20Y AVG
+12.10%
IDXX Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEXX Laboratories, Inc. (IDXX) | $43.84B | 62.05% | 61.42% | 60.55% | 59.83% |
| Humana Inc. (HUM) | $44.54B | 14.01% | 14.54% | 16.14% | 17.03% |
| Agilent Technologies, Inc. (A) | $36.21B | 53.00% | 53.36% | 52.95% | 53.14% |
| Zoetis Inc. (ZTS) | $34.27B | 70.75% | 69.79% | 68.91% | 68.46% |
| Centene Corporation (CNC) | $32.26B | 14.93% | 11.28% | 11.33% | 11.71% |
| Medline Inc. (MDLN) | $30.90B | 24.04% | 25.55% | 23.71% | 23.71% |
| IQVIA Holdings Inc. (IQV) | $30.08B | 26.11% | 30.59% | 32.75% | 33.07% |
| Biogen Inc. (BIIB) | $28.94B | 69.77% | 73.30% | 74.61% | 77.63% |
| DexCom, Inc. (DXCM) | $28.92B | 61.84% | 60.23% | 62.09% | 63.91% |
| Veeva Systems Inc. (VEEV) | $26.31B | 74.95% | 75.03% | 73.28% | 73.00% |
Gross Margin Analysis
Gross Margin
62.0%
(Revenue - COGS) / Revenue
IDEXX Laboratories, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
IDEXX Laboratories, Inc. Gross Margin FAQ
- What is the gross margin for IDEXX Laboratories, Inc. (IDXX)?
- The gross margin for IDXX stock is 62.05%.
- Is IDEXX Laboratories, Inc.'s gross margin high or low?
- IDEXX Laboratories, Inc.'s gross margin of 62.05% is in line with its 5-year average of 59.83%, near the high end of its 5-year range (58.04%–62.05%).
- What is the TTM average gross margin for IDEXX Laboratories, Inc. (IDXX)?
- The TTM average gross margin for IDXX stock is 61.42%.
- What is the 3Y average gross margin for IDEXX Laboratories, Inc. (IDXX)?
- The 3Y average gross margin for IDXX stock is 60.55%.
- What is the 5Y average gross margin for IDEXX Laboratories, Inc. (IDXX)?
- The 5Y average gross margin for IDXX stock is 59.83%.
- What is the 10Y average gross margin for IDEXX Laboratories, Inc. (IDXX)?
- The 10Y average gross margin for IDXX stock is 58.01%.
- What is the 15Y average gross margin for IDEXX Laboratories, Inc. (IDXX)?
- The 15Y average gross margin for IDXX stock is 56.72%.
- What is the 20Y average gross margin for IDEXX Laboratories, Inc. (IDXX)?
- The 20Y average gross margin for IDXX stock is 55.35%.
IDEXX Laboratories, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 61.80% |
| 2024-12-31 | 61.04% |
| 2023-12-31 | 59.82% |
| 2022-12-31 | 59.52% |
| 2021-12-31 | 58.76% |
| 2020-12-31 | 58.04% |
| 2019-12-31 | 56.73% |
| 2018-12-31 | 56.10% |
| 2017-12-31 | 55.73% |
| 2016-12-31 | 54.94% |
| 2015-12-31 | 55.58% |
| 2014-12-31 | 54.93% |
| 2013-12-31 | 54.91% |
| 2012-12-31 | 54.06% |
| 2011-12-31 | 53.05% |
| 2010-12-31 | 52.44% |
| 2009-12-31 | 51.01% |
| 2008-12-31 | 51.73% |
| 2007-12-31 | 50.24% |
| 2006-12-31 | 51.35% |
| 2005-12-31 | 50.60% |
| 2004-12-31 | 50.81% |
| 2003-12-31 | 48.38% |
| 2002-12-31 | 46.70% |
| 2001-12-31 | 47.49% |
| 2000-12-31 | 53.52% |
| 1999-12-31 | 53.71% |
| 1998-12-31 | 55.55% |
| 1997-12-31 | 54.45% |
| 1996-12-31 | 61.56% |
Related Metrics
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Jonathan J. Mazelsky